
Intensity Therapeutics, Inc. CEO to Speak at the 10th Annual Value-Based Oncology Management Forum

- Presentation to be October 14 at 4:00 PM in the Warwick Allerton Hotel in Chicago Illinois

October 12, 2015 (Westport, CT) - Intensity Therapeutics, Inc. (private), developing novel immune based drug products to treat cancer, announced that President and CEO Lewis H. Bender has been invited to give a talk at the 10th Annual Value-Based Oncology Management Forum on Wednesday, October 14, 2015 at 4:00 PM in the Warwick Allerton Hotel in Chicago Illinois. Mr. Bender's presentation is titled; ***Immuno-Oncology (IO) Beyond PD-1 Combinations – The Potential Next Generation of Immuno-Oncology.*** The talk will examine

- the current commercial IO products, products in the pipeline, and combination products,
- discuss the cancers where IO products have been successful and those indications where these drugs have been less than successful,
- a new, emerging science that may make IO work more effectively; and
- potential next generation immune system based products.

[About Intensity Therapeutics, Inc.](#)

Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer - in situ vaccination. The Company uses its DfuseRxSM platform technology to create new products capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack tumors. Further information can be found at www.intensitytherapeutics.com

Contact:

Media & Investors:

Lewis Bender

President & CEO

8 Wright Street, Suite 107

Westport, CT 06880

Tel. (203) 682-2434

Email: lbender@intensitytherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics' plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.